Public companyCompany profile · informational
Recursion Pharmaceuticals
Recursion describes itself as a clinical-stage 'TechBio' company that combines automated biology and machine learning to find drug candidates. Its most advanced program, REC-4881, is in Phase 2 testing for familial adenomatous polyposis.
Verified highlights each with its source
- Q1 2026 update (May 6, 2026) reported a median 43% reduction in polyp burden at week 13 for REC-4881 in familial adenomatous polyposis (company release).
Source: ir.recursion.com ↗ - Q2 2026 update (Aug. 5, 2026) reported Genentech opting a first neuroscience target from their collaboration into an early discovery program.
Source: ir.recursion.com ↗
Sources
- ir.recursion.comir.recursion.com
- ir.recursion.comir.recursion.com
Science and stocks are different questions. This profile describes scientific and regulatory progress. It says nothing about whether the company’s shares will rise or fall, and it is not a recommendation to buy, sell or hold any security.
Disclosure. Spin Pharma has no financial relationship with this company and holds no position in it.
